- Home
- MPB vs ORIC Comparison
MPB vs ORIC Comparison
Compare MPB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ORIC
- Stock Information
- Founded
- MPB 1868
- ORIC 2014
- Country
- MPB United States
- ORIC United States
- Employees
- MPB N/A
- ORIC N/A
- Industry
- MPB Major Banks
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- ORIC Health Care
- Exchange
- MPB Nasdaq
- ORIC Nasdaq
- Market Cap
- MPB 691.1M
- ORIC 974.1M
- IPO Year
- MPB N/A
- ORIC 2020
- Fundamental
- Price
- MPB $30.22
- ORIC $10.90
- Analyst Decision
- MPB Buy
- ORIC Strong Buy
- Analyst Count
- MPB 2
- ORIC 10
- Target Price
- MPB $34.50
- ORIC $17.33
- AVG Volume (30 Days)
- MPB 83.3K
- ORIC 895.7K
- Earning Date
- MPB 10-22-2025
- ORIC 11-11-2025
- Dividend Yield
- MPB 2.64%
- ORIC N/A
- EPS Growth
- MPB N/A
- ORIC N/A
- EPS
- MPB 2.30
- ORIC N/A
- Revenue
- MPB $191,454,000.00
- ORIC N/A
- Revenue This Year
- MPB $24.57
- ORIC N/A
- Revenue Next Year
- MPB $12.23
- ORIC N/A
- P/E Ratio
- MPB $13.18
- ORIC N/A
- Revenue Growth
- MPB 13.34
- ORIC N/A
- 52 Week Low
- MPB $22.50
- ORIC $3.90
- 52 Week High
- MPB $33.87
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- MPB 61.32
- ORIC 58.48
- Support Level
- MPB $29.92
- ORIC $10.36
- Resistance Level
- MPB $30.44
- ORIC $11.16
- Average True Range (ATR)
- MPB 0.54
- ORIC 0.51
- MACD
- MPB -0.04
- ORIC 0.06
- Stochastic Oscillator
- MPB 80.75
- ORIC 74.31
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.